These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9443305)

  • 21. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.
    Bauernfeind A; Przyklenk B
    Behring Inst Mitt; 1997 Feb; (98):256-61. PubMed ID: 9382748
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
    Ratjen F; Döring G; Nikolaizik WH
    Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.
    Ramsay KA; Sandhu H; Geake JB; Ballard E; O'Rourke P; Wainwright CE; Reid DW; Kidd TJ; Bell SC
    J Cyst Fibros; 2017 Jan; 16(1):70-77. PubMed ID: 27515017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia.
    Bucior I; Abbott J; Song Y; Matthay MA; Engel JN
    Am J Physiol Lung Cell Mol Physiol; 2013 Sep; 305(5):L352-63. PubMed ID: 23792737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pseudomonas aeruginosa and Burkholderia cepacia cannot be detected by PCR in the breath condensate of patients with cystic fibrosis.
    Vogelberg C; Hirsch T; Rösen-Wolff A; Kerkmann ML; Leupold W
    Pediatr Pulmonol; 2003 Oct; 36(4):348-52. PubMed ID: 12950050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating resistant Pseudomonas aeruginosa lung disease in young children with cystic fibrosis.
    Lim SZP; Fitzgerald DA
    Paediatr Respir Rev; 2018 Jun; 27():33-36. PubMed ID: 29033215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas aeruginosa from cystic fibrosis patients: study using whole cell RAPD and antibiotic susceptibility.
    Mereghetti L; Marquet-van der Mee N; Loulergue J; Rolland JC; Audurier A
    Pathol Biol (Paris); 1998 May; 46(5):319-24. PubMed ID: 9769892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term antibiotic treatment of patients with cystic fibrosis: a commensal organism's view.
    Moore JE; Maeda Y; Millar BC; Goldsmith CE; Coulter WA; Mason C; Elborn JS
    Br J Biomed Sci; 2009; 66(4):203-5. PubMed ID: 20095130
    [No Abstract]   [Full Text] [Related]  

  • 29. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
    Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR
    J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic susceptibility testing in early and chronic respiratory infections with Pseudomonas aeruginosa.
    Foweraker JE; Govan JR
    J Cyst Fibros; 2013 May; 12(3):302. PubMed ID: 22959655
    [No Abstract]   [Full Text] [Related]  

  • 31. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishing the diagnosis of chronic colonization with Pseudomonas aeruginosa of cystic fibrosis patients: Comparison of the European consensus criteria with genotyping of P. aeruginosa isolates.
    Jonckheere L; Schelstraete P; Van Simaey L; Van Braeckel E; Willekens J; Van Daele S; De Baets F; Vaneechoutte M
    J Cyst Fibros; 2018 Nov; 17(6):729-735. PubMed ID: 29655935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a Reduction in Susceptibility Testing for
    Ponce MC; Svendsen E; Steed L; Flume PA
    Am J Respir Crit Care Med; 2020 Jan; 201(1):114-116. PubMed ID: 31469583
    [No Abstract]   [Full Text] [Related]  

  • 34. Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.
    Hoff GE; Schiotz PO; Paulsen J
    Scand J Infect Dis; 1974; 6(4):333-7. PubMed ID: 4217466
    [No Abstract]   [Full Text] [Related]  

  • 35. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
    Hansen CR; Pressler T; Koch C; Høiby N
    J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for cystic fibrosis: case study and panel discussion.
    Kuhn RJ; Flume PA
    Pharmacotherapy; 2002 Mar; 22(3 Pt 2):86S-87S. PubMed ID: 11898886
    [No Abstract]   [Full Text] [Related]  

  • 38. Bacteriological studies of bronchial secretions in 19 cases of cystic fibrosis.
    Feigelson J; Pecau Y
    Bibl Paediatr; 1967; 86():214-26. PubMed ID: 4964164
    [No Abstract]   [Full Text] [Related]  

  • 39. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudomonas colonization in cystic fibrosis. A study of 160 patients.
    Kulczycki LL; Murphy TM; Bellanti JA
    JAMA; 1978 Jul; 240(1):30-4. PubMed ID: 96277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.